Stock Market

In a year where many retail investors turned to meme stocks and SPACs, specialty home goods retailer Williams-Sonoma (NYSE:WSM) has avoided the risk and irrational valuations seen elsewhere in the market. And WSM stock has performed extremely well in 2021. Source: designs by Jack / Shutterstock.com Shares are up 74.13% in 2021 as of the close
0 Comments
Globalstar (NYSEAMERICAN:GSAT) has been on a roller coaster ride so far in 2021. GSAT stock, a satellite communications and internet-of-things (IoT) play, zoomed from 34 cents to just over $2.50 per share during February’s “meme stock” mania. Source: NicoElNino / Shutterstock.com Then, in the spring — as this trend cooled — shares dipped back to around
0 Comments
Editor’s note: This column is part of InvestorPlace.com’s Best Stocks for 2021 contest. Louis Navellier’s pick for the contest is Fiverr International (NYSE:FVRR) stock. FVRR stock has been struggling of late, but the core reason is somewhat ironic. It’s because the pandemic is fading. Source: by InvestorPlace The U.S. added just 194,000 jobs in September, while the lowest
0 Comments
Some of the things that have happened in the last two years were incredible. The events that the pandemic brought had huge impact on Wall Street. We locked down the globe. Every crowd business on the planet completely shuttered its doors and for several months. This should have killed AMC Entertainment (NYSE:AMC) stock, but instead
0 Comments
Buzz around The Metals Company (NASDAQ:TMC) stock will remain high in the coming weeks and months. TMC stock has been volatile since its Sept. 10 SPAC (Special Purpose Acquisition Company) merger with Sustainable Opportunities Acquisition.  Source: Manu Galdamez/ShutterStock.com The merger didn’t go exactly as planned, which has undoubtedly injected increased volatility into share prices. For
0 Comments
After rising over $100 briefly this year, Cassava Sciences (NASDAQ:SAVA) stock is struggling to rebound. A long document written by the lawyer of a short-seller sent SAVA stock lower. The document challenged the accuracy of some of Cassava’s clinical results Source: Atthapon Raksthaput / Shutterstock.com Cassava has two major clinical studies underway. The top-line data
0 Comments